CRTHF - ASCO 2024 Round-Up: Some Of The Most Impactful Cancer News Out Of The Big Meeting

2024-06-06 09:07:10 ET

Summary

• AstraZeneca PLC showcased projects in two plenary lecture presentations at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, including a trial that established osimertinib as the standard of care for EGFR-mutant NSCLC.
• Bristol Myers Squibb presented the first efficacy results from the NADINA trial, showing that neoadjuvant immunotherapy with nivolumab plus ipilimumab reduced the risk of melanoma returning after surgery.
• Novartis' asciminib significantly improved the rate of major molecular response in patients with chronic myeloid leukemia.

When I was preparing my article on the biotech companies to watch at this year's Annual Meeting of the American Society of Clinical Oncology, it was based on only the abstract titles and not much on the substance, just what we could glean from having different companies be present.

In following up on this, I wanted to prepare a post-mortem highlighting some of the presentations with a likely substantial impact on the coming year in cancer care. Certainly, many articles on Seeking Alpha are going to offer individual takes on relatively narrow bits of information focused on specific companies. In this article, I want to give a rundown of some of the most impactful or surprising findings to come out of the meeting, at least in my opinion....

For further details see: